Clinical trial NCT04488107: Safety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437c
Official title: A Multicenter, Open, Single Arm Dose-escalation and Dose-expansion Study: to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of FCN-437c Alone or in Combination With Letrozole in ER+/ HER2- Advanced Breast Cancer
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Breast Neoplasms
Keywords: ER-Positive
HER2-Negative
Breast Neoplasms
Lead sponsor: Ahon Pharmaceutical Co., Ltd.
Sponsor class: OTHER
Collaborators: name: Fudan University
name: Zhejiang Cancer Hospital
name: Sir Run Run Shaw Hospital
First posted: 2020-07-27
Enrollment: 78
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: This study plans to start dose escalating from 50 mg, followed by 100, 200, 300, 450, and 600 mg as tentatively designated escalating dose groups. After the initial dose group, it is allowed to adjust the subsequent dose level according to the test data, but it will not exceed 100% dose increment. After the completion of DLT observation in each group, the next dose group and the number of cases were determined according to the safety, efficacy and PK data of the dose group. The traditional "3+3" method was used in the design of dose escalating stage, and the improved Fibonacci series was used for the dose increasing stage.
Primary purpose: TREATMENT

Brief summary: This is a multicenter, open, single arm dose escalation and dose expansion clinical study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of FCN-437c alone or in combination with letrozole in women with ER +/ HER2 - advanced breast cancer.

Detailed description: This is a multicenter, open, single arm clinical study to evaluate the safety, tolerability, and antitumor activity of FCN-437c in combination with letrozole in postmenopausal women with ER + / HER2 - advanced breast cancer, and to evaluate the PK characteristics of FCN-437c monotherapy and combined therapy.

The single drug administration period (7 days) . The continuous administration period made up of 21 days of continuous administration, followed by 7 days of withdrawal, which made up of 28 days as a treatment cycle. The evaluation was conducted every 8 weeks until one of the following happened, disease progression, intolerable toxicity, death, the researcher's decision or the patients' voluntary withdrawal from the study. The follow-up visit was conducted 30 days after the last administration. The telephone follow-up was conducted once every 3 months until the end of the study to record the survival period.

In the expansion period, FCN-437c was continuous administration per day for 21 days, followed by 7 days of withdrawal, making a treatment cycle of 28 days during which letrozole was continuously administrated 2.5 mg QD. Evaluation was conducted every 8 weeks until one of the following occurred, disease progression, intolerable toxicity, death, decision of the researcher or patients' voluntary withdrawal of the study. Follow up visit was conducted 30 days after the last administration, followed by the survival period telephone follow-up every 3 months until the end of the study.

End of of the study was defined as the last patient in the dose expansion stage took the treatment for more than one year, or terminated the treatment (depending on which occurred earlier.

At the end of the study, patients with no disease progression were determined to continue taking FCN-437c according to the clinical benefits.

Eligibility criteria: Inclusion Criteria:

* Adult (\>= 18 years old) patients diagnosed as ER +/ HER2 - advanced breast cancer, without standard treatment or unable to receive standard treatment;
* The eastern cooperative oncology group (ECOG) score is 0 or 1;
* According to RECIST version 1.1, there was at least one measurable lesion or only bone metastasis;
* The expected survival period is at least 12 weeks;
* Patients have sufficient bone marrow and organ function;
* Patients is willing and able to follow the planned visit, treatment plan, laboratory examination and other test procedures;
* Patients fully understand the study and are willing to sign the informed consent form (ICF);
* The inclusion criteria specific for the dose expansion stage are as follows.
* The postmenopausal patients (\>= 18 years old) diagnosed as ER +/ HER2 - breast cancer have evidence of local recurrence or metastasis, and are not suitable for surgical resection or radiotherapy for the purpose of cure;
* There was neither history of systematic treatment nor clinical indication for chemotherapy for patients in the dose expansion stage;
* The patients in the dose expansion stage should neither have received neoadjuvant or adjuvant endocrine therapy previously, nor have progression free survival during or after the neoadjuvant or adjuvant endocrine therapy was shorter than 12 months.

Exclusion Criteria:

* HER2 + breast cancer, either defined as by fluorescence hybridization (FISH) or detected by standard immunohistochemistry (IHC);
* History of previous CDK4 / 6 inhibitors treatment;
* Received anti-tumor chemotherapy, major surgery, radiotherapy, biological drug therapy or other research drug treatment within 28 days before enrollment;
* The toxicity of previous anti-tumor therapy has not recovered (\>= grade 2 according to NCI CTCAE version 5.0), except for hair loss; the neurotoxicity of patients who have received chemotherapy before should be restored to grade 2 or below based on NCI CTCAE version 5.0;
* The patient used CYP3A strong inhibitor or CYP3A inducer 14 days before the first dose administration;
* Cardiac dysfunction or disease are consistent with one of the following conditions such as arrhythmia with clinical significance, any risk factors increasing risk of QTc interval prolongation, or congestive heart failure (CHF) with grade ≥ 3 according to NYHA ;
* Dysphagia, active digestive system disease, major gastrointestinal surgery, malabsorption syndrome, or other conditions that may impair the absorption of FCN-437c;
* Known allergy to letrozole, FNC-437c or any other excipients;
* Uncontrolled central system metastasis;
* Active infection, including HBV, HCV, HIV, et al;
* Any other disease or condition of clinical significance (e.g., uncontrolled diabetes, active or uncontrollable infection) that the researchers believe may affect protocol compliance or affect patients' signing of ICF;
* The exclusion criteria specific for the dose expansion stage was as follows.
* Postmenopausal women with advanced breast cancer who have received neoadjuvant / adjuvant endocrine therapy and progressed less than 12 months after treatment;
* Patients with advanced breast cancer who had received systemic anti-tumor therapy including endocrine and chemotherapy (patients with ER + and HER2 - who had received aromatase inhibitors for no more than 14 days were allowed to be enrolled) ;
* Other exclusion criteria are the same as those of the dose escalation stage.

Primary outcomes:
measure: DLT within 7 days of FCN-437c monotherapy
timeFrame: 7 days
measure: DLT within 28 days of FCN-437c monotherapy
timeFrame: 28 days
measure: DLT within 28 days of FCN-437c combined therapy
timeFrame: 28 days
measure: Adverse events until the last followup
timeFrame: through study completion, assessed up to 24 months
measure: Serious and significant adverse events
timeFrame: through study completion, assessed up to 24 months
measure: Incidence of Deaths
timeFrame: through study completion, assessed up to 24 months
measure: Incidence of abnormal laboratory results
timeFrame: through study completion, assessed up to 24 months
measure: Changes of ECGs from baselines
timeFrame: through study completion, assessed up to 24 months
Secondary outcomes:
measure: Anti-tumor efficacy of monotherapy
timeFrame: through study completion, assessed up to 24 months
measure: Anti-tumor efficacy of combined treatment
timeFrame: through study completion, assessed up to 24 months
measure: FPS
timeFrame: through study completion, assessed up to 24 months
measure: OS
timeFrame: through study completion, assessed up to 24 months
measure: survival rate
timeFrame: through study completion, assessed up to 24 months
measure: DOR
timeFrame: through study completion, assessed up to 24 months
measure: CBR
timeFrame: through study completion, assessed up to 24 months
measure: Cmax of FCN-437c in monotherapy
timeFrame: through study completion, assessed up to 24 months
measure: AUC of FCN-437c in monotherapy
timeFrame: through study completion, assessed up to 24 months
measure: Cmax of FCN-437c in combined treatment
timeFrame: through study completion, assessed up to 24 months
measure: AUC of FCN-437c in combined treatment
timeFrame: through study completion, assessed up to 24 months
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Fudan University Shanghai Cancer Center
Study officials:
affiliation: Fudan University
name: Xichun Hu, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Curigliano G, Gomez Pardo P, Meric-Bernstam F, Conte P, Lolkema MP, Beck JT, Bardia A, Martinez Garcia M, Penault-Llorca F, Dhuria S, Tang Z, Solovieff N, Miller M, Di Tomaso E, Hurvitz SA. Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study. Breast. 2016 Aug;28:191-8. doi: 10.1016/j.breast.2016.06.008. Epub 2016 Jun 20.
citation: Infante JR, Cassier PA, Gerecitano JF, Witteveen PO, Chugh R, Ribrag V, Chakraborty A, Matano A, Dobson JR, Crystal AS, Parasuraman S, Shapiro GI. A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas. Clin Cancer Res. 2016 Dec 1;22(23):5696-5705. doi: 10.1158/1078-0432.CCR-16-1248. Epub 2016 Aug 19.
citation: Tamura K, Mukai H, Naito Y, Yonemori K, Kodaira M, Tanabe Y, Yamamoto N, Osera S, Sasaki M, Mori Y, Hashigaki S, Nagasawa T, Umeyama Y, Yoshino T. Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients. Cancer Sci. 2016 Jun;107(6):755-63. doi: 10.1111/cas.12932. Epub 2016 May 11.
citation: Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.
citation: Elsasser A, Regnstrom J, Vetter T, Koenig F, Hemmings RJ, Greco M, Papaluca-Amati M, Posch M. Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency. Trials. 2014 Oct 2;15:383. doi: 10.1186/1745-6215-15-383.
citation: Zhang J, Wang X, Wang X, Hui A, Wu Z, Tian L, Xu C, Yang Y, Zhang W, Hu X. Phase 1a study of the CDK4/6 inhibitor, FCN-437c, in Chinese patients with HR + /HER2- advanced breast cancer. Invest New Drugs. 2021 Dec;39(6):1549-1558. doi: 10.1007/s10637-021-01133-2. Epub 2021 Jun 9.